Can genomic medicine usher in a new era of curative treatments for neurological diseases? Experts from Sangamo give their views.

Amgen has brought the Multi-Attribute Method (MAM) into the mainstream, but what’s next for this analytical workflow. Click to read article

A breakthrough in transgenic mice opens the door to “Humabodies.”

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

How can we achieve gender parity in drug dosing?

We speak with Laertis Ikonomou and Dan Weiss about the ISCT's work to combat unproven cell therapies.

Queenie Jang reveals how the ISCT created an interactive virtual conference in under two months.

What challenges and opportunities do immunotherapy developers face?

Cell and gene therapies are now considered mainstream therapeutic modalities – with revolutionary potential. But that hasn’t always been the case…

The UK’s medicines regulator releases new guidance for Brexit.